

1. Grube M. Compliance and coping potential of cancer patients treated in liaison-consultation psychiatry. *Int J Psychiatry Med* 2006;36:211–229.
2. Spiegel D. A 43-year-old woman coping with cancer [comments]. *JAMA* 1999;282:371–378.
3. Hoffman BM, Zevon MA, Diarrigo MC, et al. Screening for distress in cancer patients: the ncen rapid-screening measure. *Psychooncology* 2004;13:792–799.
4. Jacobsen PB, Donovan KA, Trask PC, et al. Screening for psychologic distress in ambulatory cancer patients. *Cancer* 2005;103:1494–1502.
5. Bultz BD, Groff SL, Fitch M, et al. Implementing screening for distress, the 6th vital sign: a Canadian strategy for changing practice. *Psychooncology* 2011;20:463–469.
6. Jacobsen PB, Widows MR, Hann DM, et al. Posttraumatic stress disorder symptoms following bone marrow transplantation for breast cancer. *Psychosom Med* 1998;60:366–371.
7. Andrykowski MA, Cordova MJ, McGrath PC, et al. Stability and change in posttraumatic stress disorder symptoms following breast cancer treatment: a 1-year follow-up. *Psychooncology* 2000;9:69–78.
8. Green BL, Rowland JH, Krupnick JL, et al. Prevalence of posttraumatic stress disorder (PTSD) in women with breast cancer. *Psychometrics* 1998;32:102–111.
9. Koopman C, Butler LD, Classen C, et al. Traumatic stress symptoms among women with recently diagnosed primary breast cancer. *J Trauma Stress* 2002;15:277–287.
10. Cordova MJ, Andrykowski MA, Kenady DE, et al. Frequency and correlates of posttraumatic stress disorder-like systems following treatment for cancer. *J Consult Clin Psychol* 1995;63:981–986.
11. Tedeschi RG, Calhoun LG. The posttraumatic growth inventory: measuring the positive legacy of trauma. *J Traumatic Stress* 1996;9:455–471.
12. Cordova MJ, Cunningham LL, Carlson CR, et al. Social constraints, cognitive processing, and adjustment to breast cancer. *J Consult Clin Psychol* 2001;69:706–711.
13. Cordova MJ, Cunningham LL, Carlson CR, et al. Posttraumatic growth following breast cancer: a controlled comparison study. *Health Psychol* 2001;20:176–185.
14. Carver CS, Antoni MH. Finding benefit in breast cancer during the year after diagnosis predicts better adjustment 5 to 8 years after diagnosis. *Health Psychol* 2004;23:595–598.
15. Kesler SR, Bennett FC, Mahaffey ML, et al. Regional brain activation during verbal declarative memory in metastatic breast cancer. *Clin Cancer Res* 2009;15:6665–6673.
16. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand* 1983;67:361–370.
17. Zung WW. A self-rating depression scale. *Arch Gen Psychiatry* 1965;12:63–70.
18. Derogatis LR, Melisaratos N. The brief symptom inventory: an introductory report. *Psychol Med* 1983;13:595–605.
19. Holland JC, Andersen B, Breitbart WS, et al. Distress management. *J Natl Compr Cancer Netw* 2010;8:448–485.
20. Zabora J, Brintzenhofesoc K, Jacobsen P, et al. A new psychosocial screening instrument for use with cancer patients. *Psychosomatics* 2001;42:241–246.
21. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders 5th Edition*. Vol. DSM-5. Washington, DC: American Psychiatric Association; 2013.
22. Zabora J. Screening procedures for psychosocial distress. In: Holland J, ed. *Psycho-Oncology*. Oxford: Oxford University Press; 1998: 653–661.
23. Moos RH, Schaefer JA. The crisis of physical illness: an overview and conceptual approach. In: Moos RM, ed. *Coping with Physical Illness: 2: New Perspectives*. New York: Plenum Press; 1984: 3–25.
24. Trunzo JJ, Pinto BM. Social support as a mediator of optimism and distress in breast cancer survivors. *J Consult Clin Psychol* 2003;71:805–811.
25. Giese-Davis J, Koopman C, Butler L, et al. Change in emotion-regulation strategy for women with metastatic breast cancer following supportive expressive group therapy. *J Consult Clin Psychol* 2002;70:916–925.
26. Cordova MJ, Andrykowski MM. Responses to cancer diagnosis and treatment: posttraumatic stress and posttraumatic growth. *Semin Clin Neuropsychiatr* 2003;8:286–296.
27. Cordova MJ, Giese-Davis J, Golant M, et al. Mood disturbance in community cancer support groups. The role of emotional suppression and fighting spirit. *J Psychosom Res* 2003;55:461–467.
28. Valentiner DP, Holahan CJ, Moos RH. Social support, appraisals of event controllability, and coping: an integrative model. *J Personality Soc Psychol* 1994;66:1094–1102.
29. De Ridder D, Schreurs K. Developing interventions for chronically ill patients: is coping a helpful concept? *Clin Psychol Rev* 2001;21:205–240.
30. Lazarus A, Folkman S. *Stress, Appraisal, And Coping*. New York: Springer; 1984.
31. Folkman S, Moskowitz J. Positive affect and the other side of coping. *Am Psychol* 2000;55:647–654.
32. Rosenbaum E, Gautier H, Fobair P, et al. Cancer supportive care, improving the quality of life for cancer patients. A program evaluation report. *Support Care Cancer* 2004;12:293–301.
33. Holland JC. History of psycho-oncology: overcoming attitudinal and conceptual barriers. *Psychosom Med* 2002;64:206–221.
34. Spiegel D. A 43-year-old woman coping with cancer [clinical conference] [see comments]. *JAMA* 1999;282:371–378.
35. Aziz NM, Rowland JH. Trends and advances in cancer survivorship research: challenge and opportunity. *Semin Radiat Oncol* 2003;13:248–266.
36. Compas BE, Haaga DA, Keefe FJ, et al. Sampling of empirically supported psychological treatments from health psychology: smoking, chronic pain, cancer, and bulimia nervosa. *J Consult Clin Psychol* 1998;66:89–112.
37. Barsevick AM, Sweeney C, Haney E, et al. A systematic qualitative analysis of psychoeducational interventions for depression in patients with cancer. *Oncol Nurs Forum* 2002;29:73–84.
38. Devine EC, Westlake SK. The effects of psychoeducational care provided to adults with cancer: meta-analysis of 116 studies. *Oncol Nurs Forum* 1995;22:1369–1381.
39. Grunfeld E. Looking beyond survival: how are we looking at survivorship? *J Clin Oncol* 2006;24:5166–5169.
40. Andersen B. Psychological interventions for cancer patients to enhance the quality of life. *J Consult Clin Psychol* 1992;60:552–568.
41. Andersen BL, Kiecolt-Glaser JK, Glaser R. A biobehavioral model of cancer stress and disease course. *Am Psychol* 1994;49:389–404.
42. Fawzy FI, Fawzy NM, Arndt LA, et al. Critical review of psychosocial interventions in cancer care. *Arch Gen Psychiatry* 1995;52:100–113.
43. Meyer TJ, Mark MM. Effects of psychosocial interventions with adult cancer patients: a meta-analysis of randomized experiments [see comments]. *Health Psychol* 1995;14:101–108.
44. Ashby MA, Kissane DW, Beadle GF, et al. Psychosocial support, treatment of metastatic disease and palliative care [see comments]. *Med J Aust* 1996;164:43–49.
45. Linden W, Stossel C, Maurice J. Psychosocial interventions for patients with coronary artery disease: a meta-analysis [see comments]. *Arch Intern Med* 1996;156:745–752.
46. Kibby MY, Tyc VL, Mulhern RK. Effectiveness of psychological intervention for children and adolescents with chronic medical illness: a meta-analysis. *Clin Psychol Rev* 1998;18:103–117.
47. Helgeson VS, Cohen S, Schulz R, et al. Education and peer discussion group interventions and adjustment to breast cancer. *Arch Gen Psychiatry* 1999;56:340–347.
48. Helgeson VS, Cohen S, Schulz R, et al. Group support interventions for women with breast cancer: who benefits from what? *Health Psychol* 2000;19:107–114.
49. Antoni MH, Lehman JM, Kilbourn KM, et al. Cognitive-behavioral stress management intervention decreases the prevalence of depression and enhances benefit finding among women under treatment for early-stage breast cancer. *Health Psychol* 2001;20:20–32.
50. Rummans TA, Clark MM, Sloan JA, et al. Impacting quality of life for patients with advanced cancer with a structured multidisciplinary intervention: a randomized controlled trial. *J Clin Oncol* 2006;24:635–642.
51. Northouse L, Kershaw T, Mood D, et al. Effects of a family intervention on the quality of life of women with recurrent breast cancer and their family caregivers. *Psychooncology* 2005;14:478–491.
52. van Weert E, Hoekstra-Weebers J, Grol B, et al. A multidimensional cancer rehabilitation program for cancer survivors: effectiveness on health-related quality of life. *J Psychosom Res* 2005;58:485–496.
53. Lee V, Cohen SR, Edgar L, et al. Meaning-making and psychological adjustment to cancer: development of an intervention and pilot results. *Oncol Nurs Forum* 2006;33:291–302.
54. Classen C, Butler LD, Koopman C, et al. Supportive-expressive group therapy reduces distress in metastatic breast cancer patients: a randomized clinical intervention trial. *Arch Gen Psychiatry* 2001;58:494–501.
55. Kissane DW, Love A, Hatton A, et al. Effect of cognitive-existential group therapy on survival in early-stage breast cancer. *J Clin Oncol* 2004;22:4255–4260.
56. Breitbart W. Spirituality and meaning in supportive care: spirituality-and meaning-centered group psychotherapy interventions in advanced cancer. *Support Care Cancer* 2002;10:272–280.
57. Kabat-Zinn J, Massion AO, Kristeller J, et al. Effectiveness of a meditation-based stress reduction program in the treatment of anxiety disorders. *Am J Psychiatry* 1992;149:936–943.
58. Ledesma D, Kumano H. Mindfulness-based stress reduction and cancer: a meta-analysis. *Psychooncology* 2009;18:571–579.
59. Specia M, Carlson LE, Goodey E, et al. A randomized, wait-list controlled clinical trial: the effect of a mindfulness meditation-based stress reduction program on mood and symptoms of stress in cancer outpatients. *Psychosom Med* 2000;62:613–622.
60. Levine EG, Eckhardt J, Targ E. Change in post-traumatic stress symptoms following psychosocial treatment for breast cancer. *Psychooncology* 2005;14:618–635.
61. Lengacher CA, Johnson-Mallard V, Post-White J, et al. Randomized controlled trial of mindfulness-based stress reduction (mbsr) for survivors of breast cancer. *Psychooncology* 2009;18:1261–1272.
62. Carlson LE, Specia M, Faris P, et al. One year pre-post intervention follow-up of psychological, immune, endocrine and blood pressure outcomes of mindfulness-based stress reduction (MBSR) in breast and prostate cancer outpatients. *Brain Behav Immun* 2007;21:1038–1049.

63. Witek-Janusek L, Albuquerque K, Chroniak KR, et al. Effect of mindfulness based stress reduction on immune function, quality of life and coping in women newly diagnosed with early stage breast cancer. *Brain Behav Immun* 2008;22:969–981.
64. Stanton AL, Ganz PA, Kwan L, et al. Outcomes from the moving beyond cancer psychoeducational, randomized, controlled trial with breast cancer patients. *J Clin Oncol* 2005;23:6009–6018.
65. Miaskowski C, Dodd M, West C, et al. Randomized clinical trial of the effectiveness of a self-care intervention to improve cancer pain management. *J Clin Oncol* 2004;22:1713–1720.
66. Gustafson DH, Hawkins R, Pingree S, et al. Effect of computer support on younger women with breast cancer. *J Gen Intern Med* 2001;16:435–445.
67. Wagner-Johnston N. Computer/online-mediated social support for cancer-related fatigue. *J Natl Comprh Cancer Netw* 2013;11:1211–1217.
68. Lieberman MA, Golant M, Giese-Davis J, et al. Electronic support groups for breast carcinoma: a clinical trial of effectiveness. *Cancer* 2003;97:920–925.
69. Beck JS. *Cognitive Therapy: Basics and Beyond*. New York: Guilford Press; 1995.
70. Hollon SD, Shelton RC, Davis DD. Cognitive therapy for depression: conceptual issues and clinical efficacy. *J Consult Clin Psychol* 1993;61:270–275.
71. Wilson KC, Mottram PG, Vassilas CA. Psychotherapeutic treatments for older depressed people. *Cochrane Database Syst Rev* 2008;Cd004853.
72. Yalom I. *Theory And Practice Of Group Psychotherapy*. New York: Basic Books; 1995.
73. Spiegel D, Classen C. *Group Therapy For Cancer Patients: A Research-Based Handbook Of Psychosocial Care*. New York: Basic Books; 2000.
74. Grande GE, Myers LB, Sutto SR. How do patients in cancer support groups differ from those who do not? *Psychooncology* 2006;15:321–334.
75. McGovern RJ, Heyman EN, Resnick MI. An examination of coping style and quality of life of cancer patients who attend a prostate cancer support group. *J Psychosocial Oncol* 2002;20:57.
76. Yalom ID. *Existential Psychotherapy*. New York: Basic Books; 1980.
77. Moos RH, Schaefer JA. The crisis of physical illness: an overview and conceptual approach. In: Moos RH, ed. *Coping with Physical Illness: 2: New Perspectives*. New York: Plenum; 1984: 3–25.
78. Kinsinger DP, Penedo FJ, Antoni MH, et al. Psychosocial and sociodemographic correlates of benefit-finding in men treated for localized prostate cancer. *Psychooncology* 2006;15:954–961.
79. Andrykowski MA, Beacham AO, Schmidt JE, et al. Application of the theory of planned behavior to understand intentions to engage in physical and psychosocial health behaviors after cancer diagnosis. *Psychooncology* 2006;15:759–771.
80. Wellisch DK. Families and cancer. *Psychooncology* 1998;7:1–2.
81. Spiegel D, Maldonado J. Hypnosis. In: Hales, R, Yudofsky S, Talbott J, eds. *Textbook Of Psychiatry*. Washington DC: American Psychiatric Press; 1999.
82. Fallowfield LJ, Jenkins VA, Beveridge HA. Truth may hurt but deceit hurts more: communication in palliative care. *Palliat Med* 2002;16:297–303.
83. Spiegel H, Spiegel D. *Trance And Treatment: Clinical Uses Of Hypnosis*. Washington, DC: American Psychiatric Press; 1987.
84. Spiegel D, Bloom JR. Group therapy and hypnosis reduce metastatic breast carcinoma pain. *Psychosom Med* 1983;45:333–339.
85. Butler LD, Koopman C, Neri E, et al. Effects of supportive-expressive group therapy on pain in women with metastatic breast cancer. *Health Psychol* 2009;28:579–587.
86. Lang EV, Benotsch EG, Fick LJ, et al. Adjunctive non-pharmacological analgesia for invasive medical procedures: a randomised trial. *Lancet* 2000;355:1486–1490.
87. Spiegel D, Bierre P, Rootenberg J. Hypnotic alteration of somatosensory perception. *Am J Psychiatry* 1989;146:749–754.
88. Kosslyn SM, Thompson WL, Costantini-Ferrando MF, et al. Hypnotic visual illusion alters color processing in the brain. *Am J Psychiatry* 2000;157:1279–1284.
89. Carlson LE, Doll R, Stephen J, et al. Randomized controlled trial of mindfulness-based cancer recovery versus supportive expressive group therapy for distressed survivors of breast cancer (mindset). *J Clin Oncol* 2013;31:3119–3126.
90. Cunningham AJ, Edmonds CV, Jenkins GP, et al. A randomized controlled trial of the effects of group psychological therapy on survival in women with metastatic breast cancer. *Psychooncology* 1998;7:508–517.
91. Spiegel D. Mind matters in cancer survival. *JAMA* 2011;305:502–503.
92. Spiegel D, Bloom JR, Yalom I. Group support for patients with metastatic cancer: a randomized outcome study. *Arch Gen Psychiatry* 1981;38:527–533.
93. Akechi T, Okuyama T, Onishi J, et al. Psychotherapy for depression among incurable cancer patients. *Cochrane Database Syst Rev* 2008;Cd005537.
94. Spiegel D, Bloom JR, Kraemer HC, et al. Effect of psychosocial treatment on survival of patients with metastatic breast cancer. *Lancet* 1989;2:888–891.
95. Richardson JL, Shelton DR, Krailo M, et al. The effect of compliance with treatment on survival among patients with hematologic malignancies. *J Clin Oncol* 1990;8:356–364.
96. Fawzy FI, Canada AL, Fawzy NW. Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. *Arch Gen Psychiatry* 2003;60:100–103.
97. Kuchler T, Henne-Bruns D, Rappat S, et al. Impact of psychotherapeutic support on gastrointestinal cancer patients undergoing surgery: survival results of a trial. *HepatoGastroenterology* 1999;46:322–335.
98. McCorkle R, Strumpf NE, Nuamah IF, et al. A specialized home care intervention improves survival among older post-surgical cancer patients. [see comments.]. *J Am Geriatrics Society* 2000;48:1707–1713.
99. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. *Biol Psychiatry* 2003;54:283–294.
100. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. *Arch Gen Psychiatry* 1993;50:681–689.
101. Spiegel D, Butler LD, Giese-Davis J, et al. Effects of supportive-expressive group therapy on survival of patients with metastatic breast cancer: a randomized prospective trial. *Cancer* 2007;110:1130.
102. Andersen BL, Yang HC, Farrar WB, et al. Psychologic intervention improves survival for breast cancer patients: a randomized clinical trial. *Cancer* 2008;113:3450–3458.
103. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. *N Engl J Med* 2010;363:733–742.
104. Goodwin PJ, Leszcz M, Ennis M, et al. The effect of group psychosocial support on survival in metastatic breast cancer. *N Engl J Med* 2001;345:1719–1726.
105. Linn MW, Linn BS, Harris R. Effects of counseling for late stage cancer. *Cancer* 1982;49:1048–1055.
106. Ilyevskiy A, Farber N, Cheang J, et al. A randomized controlled trial of psychotherapeutic intervention in cancer patients. *Ann Royal Coll Phys Surg Canada* 1994;27:93–96.
107. Edelman S, Lemon J, Bell Dr, et al. Effects of group CBT on the survival time of patients with metastatic breast cancer. *Psychooncology* 1999;8:474–481.
108. Kissane DW, Grabsch B, Clarke DM, et al. Supportive-expressive group therapy for women with metastatic breast cancer: survival and psychosocial outcome from a randomized controlled trial. *Psychooncology* 2007;16:277–286.
109. Giese-Davis J, Collie K, Rancourt KM, et al. Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. *J Clin Oncol* 2011;29:413–420.
110. Aizer AA, Chen MH, McCarthy EP, et al. Marital status and survival in patients with cancer. *J Clin Oncol* 2013;31:3869–3876.
111. Pezzella G, Moslinger-Gehmayr R, Contu A. Treatment of depression in patients with breast cancer: a comparison between paroxetine and amitriptyline. *Breast Cancer Res Treat* 2001;70:1–10.
112. Van Gool AR, Bannink M, Stronks DL, et al. Re: Mirtazapine in cancer patients. *J Pain Symptom Manage* 2003;25:7–8.
113. Razavi D, Allilaire JF, Smith M, et al. The effect of fluoxetine on anxiety and depression symptoms in cancer patients. *Acta Psychiatr Scand* 1996;94:205–210.
114. Holland JC, Romano SJ, Heiligenstein JH, et al. A controlled trial of fluoxetine and desipramine in depressed women with advanced cancer. *Psychooncology* 1998;7:291–300.
115. Berney A, Stiefel F, Mazzocato C, et al. Psychopharmacology in supportive care of cancer: a review for the clinician. III. Antidepressants. *Support Care Cancer* 2000;8:278–286.
116. Fisch MJ, Loehrer PJ, Kristeller J, et al. Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. *J Clin Oncol* 2003;21:1937–1943.
117. Morrow GR, Hickok JT, Roscoe JA, et al. Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program. *J Clin Oncol* 2003;21:4635–4641.
118. Barton DL, Loprinzi CL, Novotny P, et al. Pilot evaluation of citalopram for the relief of hot flashes. *J Support Oncol* 2003;1:47–51.
119. Demierre MF, Taverna J. Mirtazapine and gabapentin for reducing pruritus in cutaneous t-cell lymphoma. *J Am Acad Dermatol* 2006;55:543–544.
120. McDonald AA, Portenoy RK. How to use antidepressants and anticonvulsants as adjuvant analgesics in the treatment of neuropathic cancer pain. *J Support Oncol* 2006;4:43–52.
121. Razavi D, Kormoss N, Collard A, et al. Comparative study of the efficacy and safety of trazodone versus clorazepate in the treatment of adjustment disorders in cancer patients: a pilot study. *J Int Med Res* 1999;27:264–272.
122. Capuron L, Gunnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. *Neuropsychopharmacology* 2002;26:643–652.
123. Musselman DL, Lawson DH, Gunnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. *N Engl J Med* 2001;344:961–966.
124. Krishnan KR, Delong M, Kraemer H, et al. Comorbidity of depression with other medical diseases in the elderly. *Biol Psychiatry* 2002;52:559–588.
125. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. *Biolog Psychiatry* 2003;54:269–282.
126. Rodin G, Lloyd N, Katz M, et al. The treatment of depression in cancer patients: a systematic review. *Support Care Cancer* 2007;15:123–136.
127. Ballas CA, Evans DL, Dinges DF. Psychostimulants in psychiatry: amphetamine, methylphenidate, and modafinil. In: Schatzberg AF, Nemeroff CB, eds. *The American Psychiatric Publishing Textbook Of Psychopharmacology*. 3rd ed. Washington DC: American Psychiatric Publishing; 2004: 671.

128. Henry NL, Stearns V, Flockhart DA, et al. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression. *Am J Psychiatry* 2008;165:1251–1255.
129. Jin Y, Desta Z, Stearns V, et al. Cyp2d6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. *J Natl Cancer Inst* 2005;97:30–39.
130. Goetz MP, Rae JM, Suman VJ, et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. *J Clin Oncol* 2005;23:9312–9318.
131. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. *J Natl Cancer Inst* 2003;95:1758–1764.
132. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. *BMJ* 2010;340:C693.
133. Lash TL, Pedersen L, Cronin-Fenton D, et al. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. *Br J Cancer* 2008;99:616–621.
134. Desmarais JE, Looper KJ. Interactions between tamoxifen and antidepressants via cytochrome P450 2d6. *J Clin Psychiatry* 2009;70:1688–1697.
135. Lydiatt WM, Bessette D, Schmid KK, et al. Prevention of depression with escitalopram in patients undergoing treatment for head and neck cancer: randomized, double-blind, placebo-controlled clinical trial. *JAMA Otolaryngol Head Neck Surg* 2013;139:678–686.
136. Raj A, Sheehan D. Benzodiazapines. In: Schatzberg AF, Nemeroff CB, eds. *The American Psychiatric Publishing Textbook of Psychopharmacology*. 3rd ed. Washington DC: American Psychiatric Publishing; 2004: 371.
137. Negro S, Martin A, Azuara ML, et al. Stability of tramadol and haloperidol for continuous subcutaneous infusion at home. *J Pain Symptom Manage* 2005;30:192–199.